Department of Laboratory Medicine, Medical and Health Science Center, University of Debrecen, Nagyerdei Krt. 98, 4032, Debrecen, Hungary,
J Bone Miner Metab. 2013 Sep;31(5):579-84. doi: 10.1007/s00774-013-0451-z. Epub 2013 Mar 24.
The aim of this study is to evaluate the relationship of serum sclerostin levels with age, cystatin C, bone mineral density (BMD) and biochemical markers of bone turnover in healthy Hungarian men >50 years of age. We determined serum levels of sclerostin and examined its relationship to age, cystatin C, osteocalcin, C-terminal telopeptides of type-I collagen, procollagen type 1 amino-terminal propeptide, 25-hydroxyvitamin D, parathyroid hormone, and L1-L4 (LS) and femur neck (FN) BMD data available from 194 randomly selected ambulatory men belonging to the HunMen cohort. In the study population as a whole [n = 194; age (median, range) 59 (51-81) years], statistically significant correlation was found between sclerostin and age (r = 0.211; p = 0.003), cystatin C (r = 0.246; p = 0.001), FN BMD (r = 0.147; p = 0.041) and LS BMD (r = 0.169; p = 0.019). Compared to middle-aged men (age ≤59 years, n = 98), elderly men (age >59 years, n = 96) had significantly higher serum sclerostin levels (67.8 ± 15.9 vs 63.5 ± 14 pmol/L; p = 0.047). Among men with normal (T score >-1.0) FN BMD, the elderly had significantly higher serum sclerostin levels compared to the middle-aged men (70.4 ± 17 vs 63.9 ± 11.5 pmol/L; p = 0.019). Furthermore, among the elderly men cystatin C was the only significant predictor of serum sclerostin levels (standardized regression coefficient (β) = 0.487; p < 0.001). In the studied healthy elderly cohort, this study reports a significant increase in sclerostin levels with increasing age and deteriorating kidney function as determined by plasma cystatin C levels.
本研究旨在评估健康的匈牙利男性中血清骨硬化蛋白水平与年龄、半胱氨酸蛋白酶抑制剂 C、骨密度 (BMD) 和骨转换生化标志物的关系。我们测定了血清骨硬化蛋白水平,并研究了其与年龄、半胱氨酸蛋白酶抑制剂 C、骨钙素、I 型胶原 C 端肽、前胶原 I 氨基端前肽、25-羟维生素 D、甲状旁腺激素以及 L1-L4(LS)和股骨颈(FN)BMD 的关系,这些数据来自 194 名随机选择的、属于 HunMen 队列的门诊男性。在整个研究人群中(n=194;年龄[中位数,范围]59 [51-81]岁),血清骨硬化蛋白与年龄(r=0.211;p=0.003)、半胱氨酸蛋白酶抑制剂 C(r=0.246;p=0.001)、FN BMD(r=0.147;p=0.041)和 LS BMD(r=0.169;p=0.019)呈统计学显著相关。与中年男性(年龄≤59 岁,n=98)相比,老年男性(年龄>59 岁,n=96)的血清骨硬化蛋白水平显著更高(67.8±15.9 与 63.5±14 pmol/L;p=0.047)。在 FN BMD 正常(T 评分>-1.0)的男性中,与中年男性相比,老年男性的血清骨硬化蛋白水平显著更高(70.4±17 与 63.9±11.5 pmol/L;p=0.019)。此外,在老年男性中,半胱氨酸蛋白酶抑制剂 C 是血清骨硬化蛋白水平的唯一显著预测因子(标准化回归系数(β)=0.487;p<0.001)。在本研究中,我们报告了在这个研究的健康老年队列中,随着年龄的增长和血浆半胱氨酸蛋白酶抑制剂 C 水平反映的肾功能恶化,血清骨硬化蛋白水平显著增加。